Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.

Antonarakis ES, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2011 Sep;14(3):206-18. doi: 10.1038/pcan.2011.24. Epub 2011 May 17. Review.

2.

New therapies for castration-resistant prostate cancer: efficacy and safety.

Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.

Eur Urol. 2011 Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Epub 2011 May 4. Review.

PMID:
21592649
3.

Changing therapeutic paradigms in castrate-resistant prostate cancer.

Zivi A, Massard C, De-Bono J.

Clin Genitourin Cancer. 2010 Dec 1;8(1):17-22. doi: 10.3816/CGC.2010.n.003. Review.

PMID:
21208851
4.

Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.

Antonarakis ES, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2011 Sep;14(3):192-205. doi: 10.1038/pcan.2011.23. Epub 2011 May 17. Review.

5.

Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.

MacVicar GR, Hussain MH.

Curr Opin Oncol. 2013 May;25(3):252-60. doi: 10.1097/CCO.0b013e32835ff161. Review.

PMID:
23511665
6.

[The treatment of castration-resistant prostate cancer].

Petrányi Á.

Magy Onkol. 2012 Dec;56(4):219-28. doi: MagyOnkol.2012.56.4.219. Epub 2012 Oct 3. Review. Hungarian.

7.

New strategies for medical management of castration-resistant prostate cancer.

Asmane I, Céraline J, Duclos B, Rob L, Litique V, Barthélémy P, Bergerat JP, Dufour P, Kurtz JE.

Oncology. 2011;80(1-2):1-11. doi: 10.1159/000323495. Epub 2011 May 16. Review.

PMID:
21577012
8.

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.

Ang JE, Olmos D, de Bono JS.

Br J Cancer. 2009 Mar 10;100(5):671-5. doi: 10.1038/sj.bjc.6604904. Epub 2009 Feb 17. Review.

9.

Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.

Salem M, Garcia JA.

Curr Oncol Rep. 2011 Apr;13(2):92-6. doi: 10.1007/s11912-011-0153-4. Review.

PMID:
21243537
10.

Castration-resistant prostate cancer: targeted therapies.

Leo S, Accettura C, Lorusso V.

Chemotherapy. 2011;57(2):115-27. doi: 10.1159/000323581. Epub 2011 Mar 24. Review.

PMID:
21430379
11.

Novel therapies for the treatment of advanced prostate cancer.

Clarke JM, Armstrong AJ.

Curr Treat Options Oncol. 2013 Mar;14(1):109-26. doi: 10.1007/s11864-012-0222-4. Review.

12.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
13.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

14.

The role of abiraterone in the management of metastatic castration-resistant prostate cancer.

Rawlinson A, Mohammed A, Beatty J, Bell R, Miller M.

Expert Rev Anticancer Ther. 2012 Apr;12(4):429-37. doi: 10.1586/era.12.12. Review.

PMID:
22500680
15.

Novel options for the treatment of castration-resistant prostate cancer.

Ohlmann CH, Merseburger AS, Suttmann H, Schilling D, Trojan L, Kempkensteffen C, Corvin S, Mathers MJ, Bastian PJ.

World J Urol. 2012 Aug;30(4):495-503. doi: 10.1007/s00345-011-0796-7. Epub 2011 Nov 20. Review.

PMID:
22101903
16.

Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.

Zhu H, Garcia JA.

Curr Oncol Rep. 2013 Apr;15(2):105-12. doi: 10.1007/s11912-013-0300-1. Review.

PMID:
23371447
17.

New therapies for castrate-resistant prostate cancer.

Williams SB, Lay AH, Lau CS, Josephson DY, Wilson TG, Choueiri TK, Pal SK.

Expert Opin Pharmacother. 2011 Sep;12(13):2069-74. doi: 10.1517/14656566.2011.590133. Epub 2011 Jun 11. Review.

PMID:
21663529
18.

Current, new and novel therapy for castration-resistant prostate cancer.

Gaya JM, Ahallal Y, Sanchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Bennamoun M, Cathelineau X.

Expert Rev Anticancer Ther. 2013 Jul;13(7):819-27. doi: 10.1586/14737140.2013.811154. Review.

PMID:
23875660
19.

Agents that target androgen synthesis in castration-resistant prostate cancer.

Ferraldeschi R, de Bono J.

Cancer J. 2013 Jan-Feb;19(1):34-42. doi: 10.1097/PPO.0b013e31827e0b6f. Review.

PMID:
23337755
20.

Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.

Eichholz A, Ferraldeschi R, Attard G, de Bono JS.

Mol Cell Endocrinol. 2012 Sep 5;360(1-2):68-75. doi: 10.1016/j.mce.2011.09.038. Epub 2011 Oct 1. Review.

PMID:
21986558

Supplemental Content

Support Center